ImmunoPrecise Antibodies Ltd. IPA
Oct 20, 2025, 2:54 PM EDT
- Market cap
- 74.77M
- Revenue (ttm)
- 24.09M
- Profit margin
- -115.22%
- EPS (ttm)
- -0.68
- Shares out
- 31.06M
- Forward P/E
- -2.49
- Volume
- 55.66K
- Avg volume
- 1.83M
- Open
- 1.65
- Previous close
- 1.62
- Day's range
- 1.56 – 1.65
- 52-week range
- 2.00 – 2.24
- Beta
- 0.27
- Analysts
- Buy
- Price target
- 5.00 (+208.6%)
- Earnings date
- Sep 16, 2024
Key statistics
- Enterprise value
- 23.90M
- PEG ratio
- 0.00
- Price / sales
- 0.51
- Price / book
- 0.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -7.50%
- Free cash flow
- -808.50K
- Total cash
- 3.91M
- Total debt
- 16.10M
- Return on equity
- -64.04%
- Short % of float
- 2.41%
- 50-day average
- 0.452
- 200-day average
- 0.882795
Analyst view
Consensus: buy
- Target (low)
- 3.00
- Target (mean)
- 5.00
- Target (high)
- 7.00
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Sep 16, 2024
Expected Sep 16, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 10, 2024 | Oct 1, 2024 | -0.05 | -0.07 | -0.02 | -40.00% |
| Sep 16, 2024 | Jul 1, 2024 | -0.09 | — | — | — |
| Sep 16, 2024 | Jul 1, 2024 | -0.09 | -0.11 | -0.02 | -22.22% |
| Jul 29, 2024 | Apr 1, 2024 | -0.10 | — | — | — |
| Jul 29, 2024 | Apr 1, 2024 | -0.10 | -0.52 | -0.42 | -420.00% |
| Mar 14, 2024 | Jan 1, 2024 | -0.08 | -0.08 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2024 | Benchmark | main | Speculative Buy | Speculative Buy |
| Jul 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 15, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Mar 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd., a biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform, which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. In addition, it provides phage display, a custom immune library; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development. Further, it offers a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of quality attributes. Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody chimerization for cloning and production of antibody domain; Eurofins preclinical services; hybrid service model designed to reduce time and risk with custom applications; breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts; and protein manufacturing services. The company is headquartered in Victoria, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- ipatherapeutics.com
News
12 Health Care Stocks Moving In Tuesday's Intraday Session 
12 Health Care Stocks Moving In Monday's Intraday Session 
Earnings Scheduled For July 29, 2025 
Earnings Scheduled For March 28, 2025 
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Earnings Scheduled For December 10, 2024
- Earnings Scheduled For March 14, 2024
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session 
Earnings Scheduled For December 14, 2023 
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Your note
Sign in to keep a note on IPA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ingalls & Snyder | 5.41% | 1,558,892 | 622.00K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.21% | 60,300 | 24.06K | Sep 29, 2024 |
| Bank of Montreal /CAN/ | 0.20% | 57,807 | 23.06K | Sep 29, 2024 |
| Northern Trust Corporation | 0.18% | 50,730 | 20.24K | Sep 29, 2024 |
| Cibc World Markets, Inc. | 0.14% | 41,200 | 16.44K | Sep 29, 2024 |
| Gradient Capital Advisors, LLC | 0.09% | 26,808 | 10.70K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.06% | 17,484 | 6.98K | Oct 30, 2024 |